A Randomized, Double-Blind, Third Party Open (Sponsor), Dose-Rising, Placebo-Controlled Study of the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of CXA-10 in Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2018
At a glance
- Drugs CXA 10 (Primary)
- Indications Renal impairment
- Focus Adverse reactions; Biomarker; First in man
- Sponsors Complexa
- 12 Nov 2015 According to Complexa media release, results were presented at the American Society of Nephrology's Kidney Week 2015.
- 12 Nov 2015 According to Complexa media release, status changed from recruiting to completed.
- 06 May 2014 New trial record